CNMD
CONMED Corporation39.20
-1.12-2.78%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A clarifies beats, guidance tweaks
Q&A largely reaffirmed the script, clarifying Q4's ortho beat stemmed from supply chain progress, BioBrace momentum, and new Euro launches like AIM meniscal repair, while general surgery missed on intentional portfolio pruning and OEM de-emphasis. Guidance tightened to 4.5-6% organic growth post-final 2025 numbers and GI exit tweaks versus JPM slides—no walk-backs. No major divestitures planned beyond GI; M&A interest balances organic R&D push as leverage dips below 3x. AirSeal lanes pace unevenly by geography. Management stayed crisp on concerns. Ortho supply scales next.
Key Stats
Market Cap
1.21BP/E (TTM)
19.12Basic EPS (TTM)
2.05Dividend Yield
0.02%Recent Filings
8-K
10-K
FY2025 results
CONMED drove FY2025 net sales to $1.37B, up 5.2% y/y, with orthopedic surgery at $575M (+5.6%) fueled by sports medicine and BioBrace®, while general surgery hit $800M (+4.9%) via AirSeal® and specimen bags. Gross margins slipped 1.5pp to 54.6% amid $22M inventory write-offs and $13M consulting costs for supply chain fixes, yet single-use products—86% of revenue—grew 6.4% y/y. Operating income plunged to 7.5% of sales from $41M contingent consideration swings and exec advisory fees, but cash from operations held at $171M. Debt stands at $840M (44% of cap); $649M revolver available. Q4 momentum unclear sans breakdowns. EtO sterilization limits loom for 31% of products.
8-K
Q4 sales up 7.9%, EPS mixed
CONMED reported Q4 2025 sales of $373.2M, up 7.9% reported and 7.1% constant currency, driven by 17.0% international growth while domestic rose 1.4%. GAAP EPS fell to $0.54 from $1.08; adjusted EPS climbed to $1.43 from $1.34 amid optimization costs. International surged. Full-year 2026 revenue outlook: $1.345B-$1.375B.
8-K
CONMED's 2026 guidance out
CONMED unveiled preliminary 2026 guidance at the J.P. Morgan Healthcare Conference on January 12, projecting $1,423M-$1,450M revenue (~4-6% constant currency growth) and adjusted EPS of $4.25-$4.45 after GI divestiture and tariffs. High-growth platforms like AirSeal, Buffalo Filter, and BioBrace fuel orthopedics and general surgery expansion. Guidance excludes full reconciliations. Leverage drops, boosting cash returns.
8-K
CFO Garner to exit soon
CONMED announced CFO Todd Garner's separation effective the earlier of March 15, 2026, or new CFO appointment, transitioning him to Special Advisor through November 2, 2026. Garner stays for smooth handover; no disagreements with company operations. Search underway. Severance includes 1.5x salary and bonus average.
BSX
Boston Scientific Corporation
92.95+0.76
ELMD
Electromed, Inc.
29.88+0.28
EMED
Electromedical Technologies, In
0.00+0.00
ENOV
Enovis Corporation
26.07-0.47
IRMD
iRadimed Corporation
96.87-0.15
MDNC
MEDINOTEC INC
5.00+0.00
MDT
Medtronic plc.
97.72-0.85
OFIX
Orthofix Medical Inc.
15.55-0.16
SYK
Stryker Corporation
351.69-3.62
TMCI
Treace Medical Concepts, Inc.
2.70-0.07